{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:07:45Z","timestamp":1790683665137,"version":"4.1.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10555-021-09983-1","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T09:02:42Z","timestamp":1629190962000},"page":"891-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Targeting DNA damage repair pathways in pancreas cancer"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-3912","authenticated-orcid":false,"given":"Fionnuala","family":"Crowley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-3102","authenticated-orcid":false,"given":"Wungki","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"9983_CR1","doi-asserted-by":"publisher","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","DOI":"10.3322\/caac.21654"},{"issue":"19","key":"9983_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T., Desseigne, F., Ychou, M., Bouch\u00e9, O., Guimbaud, R., B\u00e9couarn, Y., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine, 364(19), 1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"9983_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., et al. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine, 369(18), 1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"9983_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/annonc\/mdx023","volume":"28","author":"A Prawira","year":"2017","unstructured":"Prawira, A., Pugh, T. J., Stockley, T. L., & Siu, L. L. (2017). Data resources for the identification and interpretation of actionable mutations by clinicians. Annals of Oncology, 28(5), 946\u2013957. https:\/\/doi.org\/10.1093\/annonc\/mdx023","journal-title":"Annals of Oncology"},{"issue":"4","key":"9983_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","volume":"21","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian, M. J., Blais, E. M., Brody, J. R., Lyons, E., DeArbeloa, P., Hendifar, A., et al. (2020). Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial. The Lancet Oncology, 21(4), 508\u2013518. https:\/\/doi.org\/10.1016\/S1470-2045(20)30074-7","journal-title":"The Lancet Oncology"},{"issue":"8","key":"9983_CR6","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","volume":"156","author":"AD Singhi","year":"2019","unstructured":"Singhi, A. D., George, B., Greenbowe, J. R., Chung, J., Suh, J., Maitra, A., et al. (2019). Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology, 156(8), 2242-2253.e2244. https:\/\/doi.org\/10.1053\/j.gastro.2019.02.037","journal-title":"Gastroenterology"},{"issue":"7","key":"9983_CR7","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.18632\/oncotarget.2972","volume":"6","author":"GM Heestand","year":"2015","unstructured":"Heestand, G. M., & Kurzrock, R. (2015). Molecular landscape of pancreatic cancer: Implications for current clinical trials. Oncotarget, 6(7), 4553\u20134561. https:\/\/doi.org\/10.18632\/oncotarget.2972","journal-title":"Oncotarget"},{"issue":"10","key":"9983_CR8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/jnci\/djy024","volume":"110","author":"MA Lowery","year":"2018","unstructured":"Lowery, M. A., Wong, W., Jordan, E. J., Lee, J. W., Kemel, Y., Vijai, J., et al. (2018). Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. Journal of the National Cancer Institute, 110(10), 1067\u20131074. https:\/\/doi.org\/10.1093\/jnci\/djy024","journal-title":"Journal of the National Cancer Institute"},{"issue":"24","key":"9983_CR9","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1002\/cncr.29664","volume":"121","author":"EE Salo-Mullen","year":"2015","unstructured":"Salo-Mullen, E. E., O\u2019Reilly, E. M., Kelsen, D. P., Ashraf, A. M., Lowery, M. A., Yu, K. H., et al. (2015). Identification of germline genetic mutations in patients with pancreatic cancer. Cancer, 121(24), 4382\u20134388. https:\/\/doi.org\/10.1002\/cncr.29664","journal-title":"Cancer"},{"issue":"8","key":"9983_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11864-020-00763-7","volume":"21","author":"S Das","year":"2020","unstructured":"Das, S., & Cardin, D. (2020). Targeting DNA damage repair pathways in pancreatic adenocarcinoma. Current Treatment Options in Oncology, 21(8), 62. https:\/\/doi.org\/10.1007\/s11864-020-00763-7","journal-title":"Current Treatment Options in Oncology"},{"key":"9983_CR11","doi-asserted-by":"publisher","unstructured":"Dreyer, S., Paulus-Hock, V., Upstill-Goddard, R., Lampraki, E., Jamieson, N., Cooke, S., et al. (2019). Defining DNA damage repair deficiency and replication stress in pancreatic cancer. Journal of Clinical Oncology, 37(4_suppl), 285\u2013285. https:\/\/doi.org\/10.1200\/JCO.2019.37.4_suppl.285","DOI":"10.1200\/JCO.2019.37.4_suppl.285"},{"key":"9983_CR12","doi-asserted-by":"publisher","unstructured":"Heeke, A. L., Pishvaian, M. J., Lynce, F., Xiu, J., Brody, J. R., Chen, W.-J., et al. (2018). Prevalence of homologous recombination\u2013related gene mutations across multiple cancer types. JCO Precision Oncology(2), 1\u201313. https:\/\/doi.org\/10.1200\/PO.17.00286","DOI":"10.1200\/PO.17.00286"},{"issue":"5446","key":"9983_CR13","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1126\/science.286.5446.1897","volume":"286","author":"T Lindahl","year":"1999","unstructured":"Lindahl, T., & Wood, R. D. (1999). Quality control by DNA repair. Science, 286(5446), 1897\u20131905. https:\/\/doi.org\/10.1126\/science.286.5446.1897","journal-title":"Science"},{"issue":"12","key":"9983_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrc3399","volume":"12","author":"NJ Curtin","year":"2012","unstructured":"Curtin, N. J. (2012). DNA repair dysregulation from cancer driver to therapeutic target. Nature Reviews Cancer, 12(12), 801\u2013817. https:\/\/doi.org\/10.1038\/nrc3399","journal-title":"Nature Reviews Cancer"},{"issue":"17","key":"9983_CR15","doi-asserted-by":"publisher","first-page":"23312","DOI":"10.18632\/oncotarget.8196","volume":"7","author":"YK Chae","year":"2016","unstructured":"Chae, Y. K., Anker, J. F., Carneiro, B. A., Chandra, S., Kaplan, J., Kalyan, A., et al. (2016). Genomic landscape of DNA repair genes in cancer. Oncotarget, 7(17), 23312\u201323321. https:\/\/doi.org\/10.18632\/oncotarget.8196","journal-title":"Oncotarget"},{"issue":"4","key":"9983_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jnci\/djh034","volume":"96","author":"A Umar","year":"2004","unstructured":"Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., R\u00fcschoff, J., et al. (2004). Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261\u2013268. https:\/\/doi.org\/10.1093\/jnci\/djh034","journal-title":"Journal of the National Cancer Institute"},{"issue":"6349","key":"9983_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., et al. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357(6349), 409. https:\/\/doi.org\/10.1126\/science.aan6733","journal-title":"Science"},{"issue":"1","key":"9983_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J. P., et al. (2020). Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology, 38(1), 1\u201310. https:\/\/doi.org\/10.1200\/jco.19.02105","journal-title":"Journal of Clinical Oncology"},{"key":"9983_CR19","doi-asserted-by":"publisher","unstructured":"Beatty, G. L., Eghbali, S., & Kim, R. (2017). Deploying immunotherapy in pancreatic cancer: Defining mechanisms of response and resistance. American Society of Clinical Oncology Educational Book(37), 267\u2013278. https:\/\/doi.org\/10.1200\/EDBK_175232","DOI":"10.1200\/EDBK_175232"},{"issue":"7","key":"9983_CR20","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1053\/j.gastro.2018.12.038","volume":"156","author":"VP Balachandran","year":"2019","unstructured":"Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019). Broadening the impact of immunotherapy to pancreatic cancer: Challenges and opportunities. Gastroenterology, 156(7), 2056\u20132072. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.038","journal-title":"Gastroenterology"},{"issue":"2","key":"9983_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","volume":"12","author":"P Sarantis","year":"2020","unstructured":"Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G., & Karamouzis, M. V. (2020). Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World journal of gastrointestinal oncology, 12(2), 173\u2013181. https:\/\/doi.org\/10.4251\/wjgo.v12.i2.173","journal-title":"World journal of gastrointestinal oncology"},{"issue":"12","key":"9983_CR22","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1093\/annonc\/mdx503","volume":"28","author":"IH Sahin","year":"2017","unstructured":"Sahin, I. H., Askan, G., Hu, Z. I., & O\u2019Reilly, E. M. (2017). Immunotherapy in pancreatic ductal adenocarcinoma: An emerging entity? Annals of Oncology, 28(12), 2950\u20132961. https:\/\/doi.org\/10.1093\/annonc\/mdx503","journal-title":"Annals of Oncology"},{"issue":"1","key":"9983_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41467-019-08290-2","volume":"10","author":"A Yimit","year":"2019","unstructured":"Yimit, A., Adebali, O., Sancar, A., & Jiang, Y. (2019). Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs. Nature Communications, 10(1), 309. https:\/\/doi.org\/10.1038\/s41467-019-08290-2","journal-title":"Nature Communications"},{"issue":"10","key":"9983_CR24","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/s1568-7864(03)00116-2","volume":"2","author":"I Plo","year":"2003","unstructured":"Plo, I., Liao, Z. Y., Barcel\u00f3, J. M., Kohlhagen, G., Caldecott, K. W., Weinfeld, M., et al. (2003). Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst), 2(10), 1087\u20131100. https:\/\/doi.org\/10.1016\/s1568-7864(03)00116-2","journal-title":"DNA Repair (Amst)"},{"issue":"6835","key":"9983_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/35077232","volume":"411","author":"JHJ Hoeijmakers","year":"2001","unstructured":"Hoeijmakers, J. H. J. (2001). Genome maintenance mechanisms for preventing cancer. Nature, 411(6835), 366\u2013374. https:\/\/doi.org\/10.1038\/35077232","journal-title":"Nature"},{"issue":"7","key":"9983_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/cancers9070081","volume":"9","author":"BJ Sishc","year":"2017","unstructured":"Sishc, B. J., & Davis, A. J. (2017). The role of the core non-homologous end joining factors in carcinogenesis and cancer. Cancers, 9(7), 81. https:\/\/doi.org\/10.3390\/cancers9070081","journal-title":"Cancers"},{"issue":"4","key":"9983_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","volume":"47","author":"JR Chapman","year":"2012","unstructured":"Chapman, J. R., Taylor, M. R. G., & Boulton, S. J. (2012). Playing the end game: DNA double-strand break repair pathway choice. Molecular Cell, 47(4), 497\u2013510. https:\/\/doi.org\/10.1016\/j.molcel.2012.07.029","journal-title":"Molecular Cell"},{"issue":"3","key":"9983_CR28","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/gutjnl-2019-319984","volume":"70","author":"L Perkhofer","year":"2021","unstructured":"Perkhofer, L., Gout, J., Roger, E., Kude de Almeida, F., Baptista Sim\u00f5es, C., Wiesm\u00fcller, L., et al. (2021). DNA damage repair as a target in pancreatic cancer: State-of-the-art and future perspectives. Gut, 70(3), 606\u2013617. https:\/\/doi.org\/10.1136\/gutjnl-2019-319984","journal-title":"Gut"},{"issue":"1","key":"9983_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","volume":"7","author":"JS Brown","year":"2017","unstructured":"Brown, J. S., O\u2019Carrigan, B., Jackson, S. P., & Yap, T. A. (2017). Targeting DNA repair in cancer: Beyond PARP inhibitors. Cancer Discovery, 7(1), 20\u201337. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0860","journal-title":"Cancer Discovery"},{"key":"9983_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.dnarep.2015.11.019","volume":"38","author":"Z Li","year":"2016","unstructured":"Li, Z., Pearlman, A. H., & Hsieh, P. (2016). DNA mismatch repair and the DNA damage response. DNA Repair, 38, 94\u2013101. https:\/\/doi.org\/10.1016\/j.dnarep.2015.11.019","journal-title":"DNA Repair"},{"issue":"8","key":"9983_CR31","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich, K. A., & Cortez, D. (2008). ATR: An essential regulator of genome integrity. Nature Reviews Molecular Cell Biology, 9(8), 616\u2013627. https:\/\/doi.org\/10.1038\/nrm2450","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"13","key":"9983_CR32","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1093\/nar\/gks270","volume":"40","author":"L Krejci","year":"2012","unstructured":"Krejci, L., Altmannova, V., Spirek, M., & Zhao, X. (2012). Homologous recombination and its regulation. Nucleic Acids Research, 40(13), 5795\u20135818. https:\/\/doi.org\/10.1093\/nar\/gks270","journal-title":"Nucleic Acids Research"},{"issue":"8","key":"9983_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.tig.2014.06.003","volume":"30","author":"F Dietlein","year":"2014","unstructured":"Dietlein, F., Thelen, L., & Reinhardt, H. C. (2014). Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends in Genetics, 30(8), 326\u2013339. https:\/\/doi.org\/10.1016\/j.tig.2014.06.003","journal-title":"Trends in Genetics"},{"issue":"1","key":"9983_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"Knijnenburg, T. A., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., et al. (2018). Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Reports, 23(1), 239-254.e236. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.076","journal-title":"Cell Reports"},{"issue":"30","key":"9983_CR35","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","volume":"35","author":"K Shindo","year":"2017","unstructured":"Shindo, K., Yu, J., Suenaga, M., Fesharakizadeh, S., Cho, C., Macgregor-Das, A., et al. (2017). Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. Journal of clinical oncology\u202f: Official journal of the American Society of Clinical Oncology, 35(30), 3382\u20133390. https:\/\/doi.org\/10.1200\/JCO.2017.72.3502","journal-title":"Journal of clinical oncology : Official journal of the American Society of Clinical Oncology"},{"key":"9983_CR36","doi-asserted-by":"publisher","unstructured":"Margaret, A. T. (2019). NCCN guidelines updates: Pancreatic cancer. Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw, 17(5.5), 603\u2013605. https:\/\/doi.org\/10.6004\/jnccn.2019.5007","DOI":"10.6004\/jnccn.2019.5007"},{"issue":"23","key":"9983_CR37","first-page":"5360","volume":"56","author":"M Goggins","year":"1996","unstructured":"Goggins, M., Schutte, M., Lu, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., et al. (1996). Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Research, 56(23), 5360\u20135364.","journal-title":"Cancer Research"},{"issue":"2","key":"9983_CR38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1158\/2159-8290.CD-15-0402","volume":"6","author":"NJ Roberts","year":"2016","unstructured":"Roberts, N. J., Norris, A. L., Petersen, G. M., Bondy, M. L., Brand, R., Gallinger, S., et al. (2016). Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discovery, 6(2), 166\u2013175. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0402","journal-title":"Cancer Discovery"},{"issue":"7540","key":"9983_CR39","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell, N., Pajic, M., Patch, A. M., Chang, D. K., Kassahn, K. S., Bailey, P., et al. (2015). Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), 495\u2013501. https:\/\/doi.org\/10.1038\/nature14169","journal-title":"Nature"},{"issue":"1","key":"9983_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1053\/j.gastro.2015.08.056","volume":"150","author":"ES Knudsen","year":"2016","unstructured":"Knudsen, E. S., O\u2019Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2016). Genetic diversity of pancreatic ductal adenocarcinoma and opportunities for precision medicine. Gastroenterology, 150(1), 48\u201363. https:\/\/doi.org\/10.1053\/j.gastro.2015.08.056","journal-title":"Gastroenterology"},{"issue":"13","key":"9983_CR41","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-12-3020","volume":"19","author":"AL Lucas","year":"2013","unstructured":"Lucas, A. L., Shakya, R., Lipsyc, M. D., Mitchel, E. B., Kumar, S., Hwang, C., et al. (2013). High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clinical cancer research\u202f: An official journal of the American Association for Cancer Research, 19(13), 3396\u20133403. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3020","journal-title":"Clinical cancer research : An official journal of the American Association for Cancer Research"},{"issue":"3","key":"9983_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.21037\/cco.2017.06.14","volume":"6","author":"BA Krantz","year":"2017","unstructured":"Krantz, B. A., Yu, K. H., & O\u2019Reilly, E. M. (2017). Pancreas adenocarcinoma: Novel therapeutics. Chinese Clinical Oncology, 6(3), 30. https:\/\/doi.org\/10.21037\/cco.2017.06.14","journal-title":"Chinese Clinical Oncology"},{"issue":"1","key":"9983_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10637-017-0497-1","volume":"36","author":"K Lee","year":"2018","unstructured":"Lee, K., Yoo, C., Kim, K. P., Park, K. J., Chang, H. M., Kim, T. W., et al. (2018). Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: A prospective study evaluating risk category for genetic testing. Investigational New Drugs, 36(1), 163\u2013169. https:\/\/doi.org\/10.1007\/s10637-017-0497-1","journal-title":"Investigational New Drugs"},{"issue":"24","key":"9983_CR44","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.1158\/1078-0432.CCR-20-1788","volume":"26","author":"S Yadav","year":"2020","unstructured":"Yadav, S., Kasi, P. M., Bamlet, W. R., Ho, T. P., Polley, E. C., Hu, C., et al. (2020). Effect of germline mutations in homologous recombination repair genes on overall survival of patients with pancreatic adenocarcinoma. Clinical Cancer Research, 26(24), 6505. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1788","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"9983_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng0597-17","volume":"16","author":"H Oz\u00e7elik","year":"1997","unstructured":"Oz\u00e7elik, H., Schmocker, B., Di Nicola, N., Shi, X. H., Langer, B., Moore, M., et al. (1997). Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nature Genetics, 16(1), 17\u201318. https:\/\/doi.org\/10.1038\/ng0597-17","journal-title":"Nature Genetics"},{"issue":"2","key":"9983_CR46","first-page":"409","volume":"60","author":"G Lal","year":"2000","unstructured":"Lal, G., Liu, G., Schmocker, B., Kaurah, P., Ozcelik, H., Narod, S. A., et al. (2000). Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Research, 60(2), 409\u2013416.","journal-title":"Cancer Research"},{"issue":"3","key":"9983_CR47","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/jco.2008.18.5546","volume":"27","author":"CR Ferrone","year":"2009","unstructured":"Ferrone, C. R., Levine, D. A., Tang, L. H., Allen, P. J., Jarnagin, W., Brennan, M. F., et al. (2009). BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. Journal of Clinical Oncology, 27(3), 433\u2013438. https:\/\/doi.org\/10.1200\/jco.2008.18.5546","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"9983_CR48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/cncr.26191","volume":"118","author":"ZK Stadler","year":"2012","unstructured":"Stadler, Z. K., Salo-Mullen, E., Patil, S. M., Pietanza, M. C., Vijai, J., Saloustros, E., et al. (2012). Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer, 118(2), 493\u2013499. https:\/\/doi.org\/10.1002\/cncr.26191","journal-title":"Cancer"},{"issue":"1","key":"9983_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/gim.2017.85","volume":"20","author":"KG Chaffee","year":"2018","unstructured":"Chaffee, K. G., Oberg, A. L., McWilliams, R. R., Majithia, N., Allen, B. A., Kidd, J., et al. (2018). Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genetics in Medicine, 20(1), 119\u2013127. https:\/\/doi.org\/10.1038\/gim.2017.85","journal-title":"Genetics in Medicine"},{"issue":"3","key":"9983_CR50","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","volume":"148","author":"RC Grant","year":"2015","unstructured":"Grant, R. C., Selander, I., Connor, A. A., Selvarajah, S., Borgida, A., Briollais, L., et al. (2015). Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology, 148(3), 556\u2013564. https:\/\/doi.org\/10.1053\/j.gastro.2014.11.042","journal-title":"Gastroenterology"},{"issue":"6","key":"9983_CR51","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","volume":"24","author":"ZI Hu","year":"2018","unstructured":"Hu, Z. I., Shia, J., Stadler, Z. K., Varghese, A. M., Capanu, M., Salo-Mullen, E., et al. (2018). Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: Challenges and recommendations. Clinical Cancer Research, 24(6), 1326. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3099","journal-title":"Clinical Cancer Research"},{"issue":"13","key":"9983_CR52","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1200\/JCO.19.01890","volume":"38","author":"T Golan","year":"2020","unstructured":"Golan, T., Kindler, H. L., Park, J. O., Reni, M., Macarulla, T., Hammel, P., et al. (2020). Geographic and ethnic heterogeneity of germline BRCA1 or BRCA2 mutation prevalence among patients with metastatic pancreatic cancer screened for entry into the POLO trial. Journal of Clinical Oncology, 38(13), 1442\u20131454. https:\/\/doi.org\/10.1200\/JCO.19.01890","journal-title":"Journal of Clinical Oncology"},{"key":"9983_CR53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21037\/apc.2020.03.02","volume":"3","author":"T Golan","year":"2020","unstructured":"Golan, T., & Brody, J. R. (2020). Targeting homologous recombination addicted tumors: Challenges and opportunities. Annals of Pancreatic Cancer, 3, 6.","journal-title":"Annals of Pancreatic Cancer"},{"issue":"2","key":"9983_CR54","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord, C. J., & Ashworth, A. (2016). BRCAness revisited. Nature Reviews Cancer, 16(2), 110\u2013120. https:\/\/doi.org\/10.1038\/nrc.2015.21","journal-title":"Nature Reviews Cancer"},{"issue":"28","key":"9983_CR55","doi-asserted-by":"publisher","first-page":"19817","DOI":"10.18632\/oncotarget.24865","volume":"9","author":"T Kondo","year":"2018","unstructured":"Kondo, T., Kanai, M., Kou, T., Sakuma, T., Mochizuki, H., Kamada, M., et al. (2018). Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Oncotarget, 9(28), 19817\u201319825. https:\/\/doi.org\/10.18632\/oncotarget.24865","journal-title":"Oncotarget"},{"issue":"5","key":"9983_CR56","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","volume":"51","author":"DC Gulhan","year":"2019","unstructured":"Gulhan, D. C., Lee, J. J., Melloni, G. E. M., Cort\u00e9s-Ciriano, I., & Park, P. J. (2019). Detecting the mutational signature of homologous recombination deficiency in clinical samples. Nature Genetics, 51(5), 912\u2013919. https:\/\/doi.org\/10.1038\/s41588-019-0390-2","journal-title":"Nature Genetics"},{"issue":"4","key":"9983_CR57","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., et al. (2017). HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nature Medicine, 23(4), 517\u2013525. https:\/\/doi.org\/10.1038\/nm.4292","journal-title":"Nature Medicine"},{"issue":"15","key":"9983_CR58","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.Ccr-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., et al. (2016). Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clinical Cancer Research, 22(15), 3764\u20133773. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2477","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"9983_CR59","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1038\/s41598-020-59671-3","volume":"10","author":"H Takaya","year":"2020","unstructured":"Takaya, H., Nakai, H., Takamatsu, S., Mandai, M., & Matsumura, N. (2020). Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Scientific Reports, 10(1), 2757. https:\/\/doi.org\/10.1038\/s41598-020-59671-3","journal-title":"Scientific Reports"},{"issue":"10","key":"9983_CR60","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","volume":"107","author":"V Abkevich","year":"2012","unstructured":"Abkevich, V., Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., et al. (2012). Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. British journal of cancer, 107(10), 1776\u20131782. https:\/\/doi.org\/10.1038\/bjc.2012.451","journal-title":"British journal of cancer"},{"issue":"21","key":"9983_CR61","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","volume":"72","author":"T Popova","year":"2012","unstructured":"Popova, T., Mani\u00e9, E., Rieunier, G., Caux-Moncoutier, V., Tirapo, C., Dubois, T., et al. (2012). Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation. Cancer Research, 72(21), 5454. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1470","journal-title":"Cancer Research"},{"issue":"4","key":"9983_CR62","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","volume":"2","author":"NJ Birkbak","year":"2012","unstructured":"Birkbak, N. J., Wang, Z. C., Kim, J.-Y., Eklund, A. C., Li, Q., Tian, R., et al. (2012). Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discovery, 2(4), 366. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0206","journal-title":"Cancer Discovery"},{"key":"9983_CR63","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.01.220","author":"T Golan","year":"2021","unstructured":"Golan, T., O\u2019Kane, G. M., Denroche, R. E., Raitses-Gurevich, M., Grant, R. C., Holter, S., et al. (2021). Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma. Gastroenterology. https:\/\/doi.org\/10.1053\/j.gastro.2021.01.220","journal-title":"Gastroenterology"},{"key":"9983_CR64","doi-asserted-by":"publisher","unstructured":"O\u2019Kane, G. M., Denroche, R., Picardo, S. L., Zhang, A., Holter, S., Grant, R. C., et al. (2020). Homologous recombination deficiency (HRD) scoring in pancreatic ductal adenocarcinoma (PDAC) and response to chemotherapy. Journal of Clinical Oncology, 38(4_suppl), 741\u2013741. https:\/\/doi.org\/10.1200\/JCO.2020.38.4_suppl.741","DOI":"10.1200\/JCO.2020.38.4_suppl.741"},{"issue":"13","key":"9983_CR65","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","volume":"26","author":"W Park","year":"2020","unstructured":"Park, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., et al. (2020). Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clinical cancer research\u202f: An official journal of the American Association for Cancer Research, 26(13), 3239\u20133247. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0418","journal-title":"Clinical cancer research : An official journal of the American Association for Cancer Research"},{"key":"9983_CR66","doi-asserted-by":"publisher","unstructured":"Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., et al. (2021). Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Journal of Clinical Oncology, 39(3_suppl), 378\u2013378. https:\/\/doi.org\/10.1200\/JCO.2021.39.3_suppl.378","DOI":"10.1200\/JCO.2021.39.3_suppl.378"},{"issue":"1","key":"9983_CR67","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","volume":"21","author":"MB Yurgelun","year":"2019","unstructured":"Yurgelun, M. B., Chittenden, A. B., Morales-Oyarvide, V., Rubinson, D. A., Dunne, R. F., Kozak, M. M., et al. (2019). Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genetics in Medicine, 21(1), 213\u2013223. https:\/\/doi.org\/10.1038\/s41436-018-0009-5","journal-title":"Genetics in Medicine"},{"key":"9983_CR68","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0006","author":"M Javle","year":"2021","unstructured":"Javle, M., Shacham-Shmueli, E., Xiao, L., Varadhachary, G., Halpern, N., Fogelman, D., et al. (2021). Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants: Findings from 2 phase 2 nonrandomized clinical trials. JAMA oncology. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0006","journal-title":"JAMA oncology"},{"key":"9983_CR69","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari, S., & Tchounwou, P. B. (2014). Cisplatin in cancer therapy: Molecular mechanisms of action. European Journal of Pharmacology, 740, 364\u2013378. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.025","journal-title":"European Journal of Pharmacology"},{"issue":"7035","key":"9983_CR70","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434(7035), 917\u2013921. https:\/\/doi.org\/10.1038\/nature03445","journal-title":"Nature"},{"issue":"1","key":"9983_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000578","volume":"5","author":"I Pokataev","year":"2020","unstructured":"Pokataev, I., Fedyanin, M., Polyanskaya, E., Popova, A., Agafonova, J., Menshikova, S., et al. (2020). Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: Comparative analysis of published clinical studies. ESMO Open, 5(1), e000578. https:\/\/doi.org\/10.1136\/esmoopen-2019-000578","journal-title":"ESMO Open"},{"issue":"10","key":"9983_CR72","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1634\/theoncologist.2011-0185","volume":"16","author":"MA Lowery","year":"2011","unstructured":"Lowery, M. A., Kelsen, D. P., Stadler, Z. K., Yu, K. H., Janjigian, Y. Y., Ludwig, E., et al. (2011). An emerging entity: Pancreatic adenocarcinoma associated with a known BRCA mutation: Clinical descriptors, treatment implications, and future directions. The Oncologist, 16(10), 1397\u20131402. https:\/\/doi.org\/10.1634\/theoncologist.2011-0185","journal-title":"The Oncologist"},{"issue":"6","key":"9983_CR73","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan, T., Kanji, Z. S., Epelbaum, R., Devaud, N., Dagan, E., Holter, S., et al. (2014). Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. British journal of cancer, 111(6), 1132\u20131138. https:\/\/doi.org\/10.1038\/bjc.2014.418","journal-title":"British journal of cancer"},{"issue":"20","key":"9983_CR74","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1158\/1078-0432.Ccr-17-0899","volume":"23","author":"MA Lowery","year":"2017","unstructured":"Lowery, M. A., Jordan, E. J., Basturk, O., Ptashkin, R. N., Zehir, A., Berger, M. F., et al. (2017). Real-time genomic profiling of pancreatic ductal adenocarcinoma: Potential actionability and correlation with clinical phenotype. Clinical Cancer Research, 23(20), 6094\u20136100. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-0899","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"9983_CR75","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balma\u00f1a, J., Castroviejo-Bermejo, M., et al. (2019). A decade of clinical development of PARP inhibitors in perspective. Annals of Oncology, 30(9), 1437\u20131447. https:\/\/doi.org\/10.1093\/annonc\/mdz192","journal-title":"Annals of Oncology"},{"issue":"22","key":"9983_CR76","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","volume":"26","author":"A Ashworth","year":"2008","unstructured":"Ashworth, A. (2008). A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. Journal of Clinical Oncology, 26(22), 3785\u20133790. https:\/\/doi.org\/10.1200\/JCO.2008.16.0812","journal-title":"Journal of Clinical Oncology"},{"issue":"26","key":"9983_CR77","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., et al. (2018). Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 379(26), 2495\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1810858","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"9983_CR78","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., et al. (2019). Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. New England Journal of Medicine, 381(4), 317\u2013327. https:\/\/doi.org\/10.1056\/NEJMoa1903387","journal-title":"New England Journal of Medicine"},{"key":"9983_CR79","doi-asserted-by":"publisher","unstructured":"Hall, M. J., Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., et al. (2020). Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial. Journal of Clinical Oncology, 38(4_suppl), 648\u2013648. https:\/\/doi.org\/10.1200\/JCO.2020.38.4_suppl.648","DOI":"10.1200\/JCO.2020.38.4_suppl.648"},{"issue":"22","key":"9983_CR80","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., et al. (2016). Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine, 375(22), 2154\u20132164. https:\/\/doi.org\/10.1056\/NEJMoa1611310","journal-title":"New England Journal of Medicine"},{"key":"9983_CR81","doi-asserted-by":"publisher","unstructured":"Binder, K. A. R., Mick, R., Hara, M., Teitelbaum, U., Karasic, T., Schneider, C., et al. (2019). Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in <em>BRCA1, BRCA2<\/em> or <em>PALB2<\/em&gt. Cancer Research, 79(13 Supplement), CT234. https:\/\/doi.org\/10.1158\/1538-7445.AM2019-CT234","DOI":"10.1158\/1538-7445.AM2019-CT234"},{"issue":"3","key":"9983_CR82","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/jco.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balma\u00f1a, J., et al. (2015). Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. Journal of Clinical Oncology, 33(3), 244\u2013250. https:\/\/doi.org\/10.1200\/jco.2014.56.2728","journal-title":"Journal of Clinical Oncology"},{"key":"9983_CR83","doi-asserted-by":"publisher","unstructured":"Shroff, R. T., Hendifar, A., McWilliams, R. R., Geva, R., Epelbaum, R., Rolfe, L., et al. (2018). Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precision Oncology, 2018.https:\/\/doi.org\/10.1200\/po.17.00316","DOI":"10.1200\/po.17.00316"},{"key":"9983_CR84","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2017.11.004","volume":"89","author":"MA Lowery","year":"2018","unstructured":"Lowery, M. A., Kelsen, D. P., Capanu, M., Smith, S. C., Lee, J. W., Stadler, Z. K., et al. (2018). Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. European Journal of Cancer, 89, 19\u201326. https:\/\/doi.org\/10.1016\/j.ejca.2017.11.004","journal-title":"European Journal of Cancer"},{"key":"9983_CR85","doi-asserted-by":"publisher","unstructured":"O\u2019Reilly, E. M., Lowery, M. A., Segal, M. F., Smith, S. C., Moore, M. J., Kindler, H. L., et al. (2014). Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC). Journal of Clinical Oncology, 32(15_suppl), 4023\u20134023. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.4023","DOI":"10.1200\/jco.2014.32.15_suppl.4023"},{"issue":"27","key":"9983_CR86","doi-asserted-by":"publisher","first-page":"44073","DOI":"10.18632\/oncotarget.17237","volume":"8","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Myzak, M. C., Johnson, B. A., 3rd., De Jesus-Acosta, A., Le, D. T., Jaffee, E. M., et al. (2017). Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget, 8(27), 44073\u201344081. https:\/\/doi.org\/10.18632\/oncotarget.17237","journal-title":"Oncotarget"},{"key":"9983_CR87","doi-asserted-by":"publisher","unstructured":"Chiorean, E. G., Guthrie, K. A., Philip, P. A., Swisher, E. M., Jalikis, F., Pishvaian, M. J., et al. (2019). Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513. Journal of Clinical Oncology, 37(15_suppl), 4014\u20134014. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.4014","DOI":"10.1200\/JCO.2019.37.15_suppl.4014"},{"issue":"3","key":"9983_CR88","first-page":"168","volume":"18","author":"GT Moffat","year":"2020","unstructured":"Moffat, G. T., & O\u2019Reilly, E. M. (2020). The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma. Clinical Advances in Hematology & Oncology, 18(3), 168\u2013179.","journal-title":"Clinical Advances in Hematology & Oncology"},{"issue":"19","key":"9983_CR89","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1158\/1078-0432.CCR-20-1301","volume":"26","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian, M. J., Wang, H., He, A. R., Hwang, J. J., Smaglo, B. G., Kim, S. S., et al. (2020). A phase I\/II study of veliparib (ABT-888) in combination with 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer. Clinical Cancer Research, 26(19), 5092. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1301","journal-title":"Clinical Cancer Research"},{"issue":"13","key":"9983_CR90","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/jco.19.02931","volume":"38","author":"EM O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly, E. M., Lee, J. W., Zalupski, M., Capanu, M., Park, J., Golan, T., et al. (2020). Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation. Journal of Clinical Oncology, 38(13), 1378\u20131388. https:\/\/doi.org\/10.1200\/jco.19.02931","journal-title":"Journal of Clinical Oncology"},{"key":"9983_CR91","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ebiom.2018.12.060","volume":"40","author":"R Tuli","year":"2019","unstructured":"Tuli, R., Shiao, S. L., Nissen, N., Tighiouart, M., Kim, S., Osipov, A., et al. (2019). A phase 1 study of veliparib, a PARP-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. eBioMedicine, 40, 375\u2013381. https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.060","journal-title":"eBioMedicine"},{"issue":"1","key":"9983_CR92","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li, H., Liu, Z.-Y., Wu, N., Chen, Y.-C., Cheng, Q., & Wang, J. (2020). PARP inhibitor resistance: The underlying mechanisms and clinical implications. Molecular Cancer, 19(1), 107\u2013107. https:\/\/doi.org\/10.1186\/s12943-020-01227-0","journal-title":"Molecular Cancer"},{"key":"9983_CR93","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","volume":"71","author":"AD D\u2019Andrea","year":"2018","unstructured":"D\u2019Andrea, A. D. (2018). Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair, 71, 172\u2013176. https:\/\/doi.org\/10.1016\/j.dnarep.2018.08.021","journal-title":"DNA Repair"},{"issue":"4","key":"9983_CR94","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.cell.2018.03.050","volume":"173","author":"R Gupta","year":"2018","unstructured":"Gupta, R., Somyajit, K., Narita, T., Maskey, E., Stanlie, A., Kremer, M., et al. (2018). DNA repair network analysis reveals shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity. Cell, 173(4), 972-988.e923. https:\/\/doi.org\/10.1016\/j.cell.2018.03.050","journal-title":"Cell"},{"key":"9983_CR95","doi-asserted-by":"publisher","unstructured":"Kaplan, A. R., Gueble, S. E., Liu, Y., Oeck, S., Kim, H., Yun, Z., et al. (2019). Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51. Sci Transl Med, 11(492). https:\/\/doi.org\/10.1126\/scitranslmed.aav4508","DOI":"10.1126\/scitranslmed.aav4508"},{"issue":"24","key":"9983_CR96","doi-asserted-by":"publisher","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","volume":"65","author":"RS Bindra","year":"2005","unstructured":"Bindra, R. S., Gibson, S. L., Meng, A., Westermark, U., Jasin, M., Pierce, A. J., et al. (2005). Hypoxia-induced down-regulation of <em>BRCA1<\/em> expression by E2Fs. Cancer Research, 65(24), 11597. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2119","journal-title":"Cancer Research"},{"issue":"5","key":"9983_CR97","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1073\/pnas.0904783107","volume":"107","author":"DC Hegan","year":"2010","unstructured":"Hegan, D. C., Lu, Y., Stachelek, G. C., Crosby, M. E., Bindra, R. S., & Glazer, P. M. (2010). Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proceedings of the National Academy of Sciences, 107(5), 2201. https:\/\/doi.org\/10.1073\/pnas.0904783107","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"9983_CR98","doi-asserted-by":"publisher","first-page":"v894","DOI":"10.1093\/annonc\/mdz394.053","volume":"30","author":"IL Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. L., Pautier, P., Pignata, S., P\u00e9rol, D., Gonz\u00e1lez-Mart\u00edn, A., Sevelda, P., et al. (2019). LBA2_PR - Phase III PAOLA-1\/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Annals of Oncology, 30, v894\u2013v895. https:\/\/doi.org\/10.1093\/annonc\/mdz394.053","journal-title":"Annals of Oncology"},{"issue":"16","key":"9983_CR99","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-19-4121","volume":"26","author":"S Lheureux","year":"2020","unstructured":"Lheureux, S., Oaknin, A., Garg, S., Bruce, J. P., Madariaga, A., Dhani, N. C., et al. (2020). EVOLVE: A multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clinical Cancer Research, 26(16), 4206. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-4121","journal-title":"Clinical Cancer Research"},{"key":"9983_CR100","doi-asserted-by":"publisher","unstructured":"Liu, J. F., Brady, M. F., Matulonis, U. A., Miller, A., Kohn, E. C., Swisher, E. M., et al. (2020). A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology, 38(15_suppl), 6003\u20136003. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.6003","DOI":"10.1200\/JCO.2020.38.15_suppl.6003"},{"key":"9983_CR101","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/fimmu.2015.00422","volume":"6","author":"E V\u00e9n\u00e9reau","year":"2015","unstructured":"V\u00e9n\u00e9reau, E., Ceriotti, C., & Bianchi, M. E. (2015). DAMPs from cell death to new life. Frontiers in Immunology, 6, 422\u2013422. https:\/\/doi.org\/10.3389\/fimmu.2015.00422","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"9983_CR102","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jtho.2019.05.004","volume":"14","author":"CM Gay","year":"2019","unstructured":"Gay, C. M., & Byers, L. A. (2019). PARP inhibition combined with immune checkpoint blockade in SCLC: Oasis in an immune desert or mirage? Journal of Thoracic Oncology, 14(8), 1323\u20131326. https:\/\/doi.org\/10.1016\/j.jtho.2019.05.004","journal-title":"Journal of Thoracic Oncology"},{"key":"9983_CR103","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3389\/fonc.2020.00570","volume":"10","author":"P Vikas","year":"2020","unstructured":"Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020). Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Frontiers in Oncology, 10, 570\u2013570. https:\/\/doi.org\/10.3389\/fonc.2020.00570","journal-title":"Frontiers in Oncology"},{"issue":"5","key":"9983_CR104","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.immuni.2016.04.010","volume":"44","author":"SS Ho","year":"2016","unstructured":"Ho, S. S., Zhang, W. Y., Tan, N. Y., Khatoo, M., Suter, M. A., Tripathi, S., et al. (2016). The DNA structure-specific endonuclease MUS81 mediates DNA sensor STING-dependent host rejection of prostate cancer cells. Immunity, 44(5), 1177\u20131189. https:\/\/doi.org\/10.1016\/j.immuni.2016.04.010","journal-title":"Immunity"},{"issue":"7","key":"9983_CR105","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","volume":"7","author":"KW Mouw","year":"2017","unstructured":"Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D\u2019Andrea, A. D. (2017). DNA Damage and repair biomarkers of immunotherapy response. Cancer Discovery, 7(7), 675\u2013693. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0226","journal-title":"Cancer Discovery"},{"issue":"14","key":"9983_CR106","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.Ccr-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M. K., Hsu, J. M., et al. (2017). PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clinical Cancer Research, 23(14), 3711\u20133720. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-3215","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"9983_CR107","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato, H., Niimi, A., Yasuhara, T., Permata, T. B. M., Hagiwara, Y., Isono, M., et al. (2017). DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nature Communications, 8(1), 1751. https:\/\/doi.org\/10.1038\/s41467-017-01883-9","journal-title":"Nature Communications"},{"issue":"9","key":"9983_CR108","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/s1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek, S. M., Postel-Vinay, S., Im, S. A., Park, Y. H., Delord, J. P., Italiano, A., et al. (2020). Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): An open-label, multicentre, phase 1\/2, basket study. The Lancet Oncology, 21(9), 1155\u20131164. https:\/\/doi.org\/10.1016\/s1470-2045(20)30324-7","journal-title":"The Lancet Oncology"},{"key":"9983_CR109","doi-asserted-by":"publisher","first-page":"v485","DOI":"10.1093\/annonc\/mdz253.016","volume":"30","author":"Y Drew","year":"2019","unstructured":"Drew, Y., Kaufman, B., Banerjee, S., Lortholary, A., Hong, S. H., Park, Y. H., et al. (2019). 1190PD\u2014Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). Annals of Oncology, 30, v485\u2013v486. https:\/\/doi.org\/10.1093\/annonc\/mdz253.016","journal-title":"Annals of Oncology"},{"issue":"1","key":"9983_CR110","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim, H., Xu, H., George, E., Hallberg, D., Kumar, S., Jagannathan, V., et al. (2020). Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nature Communications, 11(1), 3726. https:\/\/doi.org\/10.1038\/s41467-020-17127-2","journal-title":"Nature Communications"},{"key":"9983_CR111","doi-asserted-by":"publisher","unstructured":"Sun, C., Fang, Y., Yin, J., Chen, J., Ju, Z., Zhang, D., et al. (2017). Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Science translational medicine, 9(392), eaal5148. https:\/\/doi.org\/10.1126\/scitranslmed.aal5148","DOI":"10.1126\/scitranslmed.aal5148"},{"issue":"9","key":"9983_CR112","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","volume":"17","author":"SF Johnson","year":"2016","unstructured":"Johnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., et al. (2016). CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Reports, 17(9), 2367\u20132381. https:\/\/doi.org\/10.1016\/j.celrep.2016.10.077","journal-title":"Cell Reports"},{"key":"9983_CR113","doi-asserted-by":"publisher","unstructured":"Rundle, S., Bradbury, A., Drew, Y., & Curtin, N. J. (2017). Targeting the ATR-CHK1 axis in cancer therapy. Cancers, 9(5). https:\/\/doi.org\/10.3390\/cancers9050041","DOI":"10.3390\/cancers9050041"},{"issue":"1","key":"9983_CR114","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","volume":"40","author":"E Fokas","year":"2014","unstructured":"Fokas, E., Prevo, R., Hammond, E. M., Brunner, T. B., McKenna, W. G., & Muschel, R. J. (2014). Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treatment Reviews, 40(1), 109\u2013117. https:\/\/doi.org\/10.1016\/j.ctrv.2013.03.002","journal-title":"Cancer Treatment Reviews"},{"issue":"6","key":"9983_CR115","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1124\/mol.105.012716","volume":"68","author":"LM Karnitz","year":"2005","unstructured":"Karnitz, L. M., Flatten, K. S., Wagner, J. M., Loegering, D., Hackbarth, J. S., Arlander, S. J. H., et al. (2005). Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Molecular Pharmacology, 68(6), 1636. https:\/\/doi.org\/10.1124\/mol.105.012716","journal-title":"Molecular Pharmacology"},{"issue":"1","key":"9983_CR116","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/1535-7163.MCT-08-0662","volume":"8","author":"LA Parsels","year":"2009","unstructured":"Parsels, L. A., Morgan, M. A., Tanska, D. M., Parsels, J. D., Palmer, B. D., Booth, R. J., et al. (2009). Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Molecular Cancer Therapeutics, 8(1), 45. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0662","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"9983_CR117","doi-asserted-by":"publisher","first-page":"9930","DOI":"10.1038\/s41598-020-66018-5","volume":"10","author":"D-H Ha","year":"2020","unstructured":"Ha, D.-H., Min, A., Kim, S., Jang, H., Kim, S. H., Kim, H.-J., et al. (2020). Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. Scientific Reports, 10(1), 9930. https:\/\/doi.org\/10.1038\/s41598-020-66018-5","journal-title":"Scientific Reports"},{"issue":"29","key":"9983_CR118","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.19.00730","volume":"37","author":"KC Cuneo","year":"2019","unstructured":"Cuneo, K. C., Morgan, M. A., Sahai, V., Schipper, M. J., Parsels, L. A., Parsels, J. D., et al. (2019). Dose escalation trial of the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. Journal of Clinical Oncology, 37(29), 2643\u20132650. https:\/\/doi.org\/10.1200\/JCO.19.00730","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"9983_CR119","doi-asserted-by":"publisher","first-page":"599","DOI":"10.18433\/jpps30684","volume":"22","author":"G Guney Eskiler","year":"2019","unstructured":"Guney Eskiler, G. (2019). The interaction of PI3K inhibition with homologous recombination repair in triple negative breast cancer cells. Journal of Pharmacy & Pharmaceutical Sciences, 22(1), 599\u2013611. https:\/\/doi.org\/10.18433\/jpps30684","journal-title":"Journal of Pharmacy & Pharmaceutical Sciences"},{"issue":"7","key":"9983_CR120","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/1078-0432.Ccr-15-1772","volume":"22","author":"W Mo","year":"2016","unstructured":"Mo, W., Liu, Q., Lin, C. C., Dai, H., Peng, Y., Liang, Y., et al. (2016). mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clinical Cancer Research, 22(7), 1699\u20131712. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1772","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"9983_CR121","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1593\/neo.131694","volume":"16","author":"P De","year":"2014","unstructured":"De, P., Sun, Y., Carlson, J. H., Friedman, L. S., Leyland-Jones, B. R., & Dey, N. (2014). Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. Neoplasia, 16(1), 43\u201372. https:\/\/doi.org\/10.1593\/neo.131694","journal-title":"Neoplasia"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-021-09983-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-021-09983-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-021-09983-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T09:19:33Z","timestamp":1635499173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-021-09983-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["9983"],"URL":"https:\/\/doi.org\/10.1007\/s10555-021-09983-1","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"8 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FC: No conflicts of interest to declare.WP: Research funding to institution: Merck, Astellas, Gossamerbio.EOR: Research funding to MSK: Genentech\/Roche, Celgene\/BMS, BioNTech, BioAtla, AstraZeneca, Arcus, Elicio. Consulting Role: Cytomx Therapeutics (DSMB), Rafael Therapeutics (DSMB), Sobi, Silenseed, Molecular Templates, Boehringer Ingelheim, BioNTech, Ipsen, Polaris, Tyme, Seagen, Merck, AstraZeneca, Noxxon, BioSapien, Bayer (spouse), Genentech-Roche (spouse), Celgene-BMS (spouse), Eisai (spouse).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}